pegylated liposomal doxorubicin (PLD) + PD-1

Phase 2UNKNOWN

1 views this week 0 watching💤 Quiet

Interest: 31/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Muscle Invasive Bladder Cancer

Conditions

Muscle Invasive Bladder Cancer

Trial Timeline

Sep 17, 2019 → May 31, 2021

NCT ID

NCT04101812

About pegylated liposomal doxorubicin (PLD) + PD-1

pegylated liposomal doxorubicin (PLD) + PD-1 is a phase 2 stage product being developed by CSPC Pharmaceutical Group Limited for Muscle Invasive Bladder Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT04101812. Target conditions include Muscle Invasive Bladder Cancer.

What happened to similar drugs?

2 of 20 similar drugs in Muscle Invasive Bladder Cancer were approved

Approved (2) Terminated (0) Active (18)

✅Botulinum toxin type A + PlaceboIpsenApproved

✅prabotulinumtoxinA-xvfsEvolusApproved

🔄Pembrolizumab + Enfortumab VedotinAstellas PharmaPhase 3

🔄EperisoneEisaiPhase 3

🔄Botulinum Toxin Type AAbbViePhase 3

🔄BOTOX + PlaceboAbbViePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04101812	Phase 2	UNKNOWN	Sep 17, 2019	May 31, 2021	Muscle Invasive Bladder Cancer

Competing Products

20 competing products in Muscle Invasive Bladder Cancer

See all competitors

Product	Company	Stage	Hype Score
Enfortumab vedotin + Pembrolizumab	Astellas Pharma	Phase 2	42
Enfortumab Vedotin + Pembrolizumab	Astellas Pharma	Phase 2	42
Pembrolizumab + Enfortumab Vedotin	Astellas Pharma	Phase 3	44
Eperisone	Eisai	Phase 3	40
LY2495655 + Placebo	Eli Lilly	Phase 2	35
HRS-9190	Jiangsu Hengrui Medicine	Phase 1	29
HRS-9190 for Injection	Jiangsu Hengrui Medicine	Phase 1	29
Botulinum Toxin Type A	AbbVie	Phase 3	40
BOTOX + Placebo	AbbVie	Phase 3	40
BOTOX + Placebo	AbbVie	Phase 3	40
BOTOX + Placebo for BOTOX	AbbVie	Phase 3	40
BOTOX + Placebo	AbbVie	Phase 3	40
Durvalumab + Tremelimumab + Enfortumab Vedotin	AstraZeneca	Phase 3	44
Durvalumab (MEDI4736) + Bacillus Calmette-Guerin (BCG)	AstraZeneca	Phase 3	44
Durvalumab + Oleclumab	AstraZeneca	Phase 1	29
AZD4547 + MEDI4736 + Olaparib + AZD1775 + Vistusertib + AZD9150 + Selumetinib	AstraZeneca	Phase 1	33
Durvalumab + Cisplatin + Gemcitabine	AstraZeneca	Phase 3	44
Durvalumab + BCG	AstraZeneca	Phase 3	44
Durvalumab + Monalizumab	AstraZeneca	Phase 2	42
Durvalumab (Imfinzi) + Tremelimumab	AstraZeneca	Phase 2	27